Kidney Transplant Surgery Recovery, Weeks 3–6: Stabilization and Graft Optimization
Weeks 3–6 after kidney transplant surgery make up phase 2 of 4 in a typical 12-week recovery: Stabilization and Graft Optimization. Your own surgeon's instructions always come first.
Goals for weeks 3–6
- By the third week, tacrolimus levels should be consistently within the target range, and dose adjustments become less frequent. You will begin to develop a feel for the timing and rhythm of your medication regimen, which at this point may include 10 to 15 different medications taken at specific times throughout the day. Building this into a sustainable daily routine is critical, because you will take immunosuppressive medications for the rest of your life. Many patients find that pill organizers, smartphone alarms, and pharmacy delivery services help maintain consistency. Some transplant centers offer smartphone applications that track medication adherence and lab results — use every tool available.
- Mycophenolate commonly causes gastrointestinal side effects, most frequently diarrhea but also nausea, abdominal cramping, and loss of appetite. These symptoms are dose-dependent and are most common in the first weeks to months. If gastrointestinal symptoms are significantly affecting your quality of life or hydration status, inform your transplant team — dose adjustments, splitting doses, or switching to enteric-coated mycophenolate sodium can often help without compromising immune suppression.
- Prednisone is typically started at moderate doses and tapered gradually over the first three to six months. Some centers taper to a low maintenance dose (5 mg daily); others pursue complete steroid withdrawal in selected low-risk patients. The side effects of corticosteroids — insomnia, mood changes, increased appetite, weight gain, glucose intolerance, bone thinning, skin fragility, and cushingoid appearance — are dose-dependent and improve with tapering. Be aware that steroid tapering can itself cause symptoms: fatigue, joint aches, and mild depression are common as the body readjusts to lower steroid levels.
- Your ureteral stent will be removed by cystoscopy, typically at 4 to 6 weeks post-transplant. This is a brief outpatient procedure performed under local anesthesia with or without sedation. A small flexible scope is passed through the urethra into the bladder, and the stent is grasped and removed. The procedure takes a few minutes and causes mild discomfort and temporary urinary symptoms (frequency, urgency, and mild hematuria) that resolve within 24 to 48 hours. Some patients experience a brief episode of graft site aching after stent removal as the ureter adjusts. This is normal and resolves quickly.
- Post-transplant hypertension affects the majority of kidney transplant recipients and results from the combined effects of tacrolimus (which causes vasoconstriction), corticosteroids (which cause fluid retention), and the underlying vascular disease that contributed to kidney failure in many patients. Blood pressure should be monitored at home twice daily and recorded for transplant team review. Target blood pressure is typically below 130/80 mmHg. Calcium channel blockers are often the first-line antihypertensive choice because they counteract tacrolimus-mediated vasoconstriction, though note that diltiazem and verapamil increase tacrolimus levels and require tacrolimus dose reduction.
- New-onset diabetes after transplant (NODAT) occurs in approximately 10 to 30 percent of kidney transplant recipients and is driven primarily by tacrolimus and corticosteroid effects on glucose metabolism. Patients with pre-existing risk factors (obesity, family history, certain ethnic backgrounds) are at highest risk. Blood glucose monitoring should be performed regularly during this phase, and any consistently elevated readings should be reported. Early identification and management of NODAT — through lifestyle modification, oral hypoglycemics, or insulin — is important because uncontrolled hyperglycemia damages both the transplanted kidney and cardiovascular system.
- Dyslipidemia is common post-transplant, driven by corticosteroids, calcineurin inhibitors, and the metabolic milieu of chronic kidney disease. Lipid panels should be monitored and treated according to transplant team guidance. Statins are commonly used but require awareness of drug interactions (some statins are significantly affected by calcineurin inhibitor levels).
- By week 3 to 4, most patients feel substantially better and are eager to increase their activity level. Walking should progress from the short distances tolerated in Phase 1 to 20 to 30 minutes of continuous walking daily. Stairs are manageable. Light household activities can resume. The incision should be comfortably healed by the end of this phase, though deep tissue healing continues for several more weeks. Continue to avoid lifting anything heavier than 5 kg and avoid activities that could result in direct trauma to the graft site.
What to avoid in weeks 3–6
- Continue 5 kg lifting restriction through week 6
- No contact sports or activities with pelvic/abdominal trauma risk
- Continue all immunosuppression exactly as prescribed
- Continue infection precautions (hand hygiene, food safety, avoiding sick contacts)
- No NSAIDs (lifelong)
- No grapefruit (lifelong)
- No new medications or supplements without transplant team approval
- Sun protection (increased skin cancer risk begins now and is lifelong)
← Weeks 1–2: Inpatient and Early Post-Discharge Recovery · Weeks 7–12: Rehabilitation and Lifestyle Integration →
See the whole recovery timeline →
Follow weeks 3–6 in Surgily
Surgily shows each day's exercises for this phase, lets you log how you feel in 30 seconds and share it with your care team, and tells you clearly when to get help.
Get my recovery plan →